Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CLBX.L
STRONG SELLCelLBxHealth plc · Healthcare · United Kingdom · $39M · Avg Vol: $28K/d
COMPANY DESCRIPTION
CellBxHealth plc is a UK-based healthcare company specializing in the development of early-stage diagnostic tools and cellular health monitoring technologies. The company's competitive advantage is its proprietary cellular analysis platform designed to detect early physiological changes before clinical symptoms manifest. CellBxHealth operates as a niche diagnostics developer targeting the preventative medicine and wellness sectors.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.3M | 1.4M | 2.9M | 3.8M | 1.8M | 7.5% | 1.5M | 28.6M | 49.8M | 428.6% |
| EPS | -0.01 | -0.03 | -0.02 | -0.02 | -0.07 | — | -0.04 | — | — | — |
| Shares | 1.9B | 1.1B | 1.1B | 1.1B | 1.1B | -41.6% | 1.1B | — | — | — |
| Debt | 3.1M | 6.6M | 6.0M | 5.6M | 2.4M | -6.1% | 1.7M | — | — | — |
| Equity | 53.2M | 52.9M | 30.3M | 24.3M | 9.5M | -35.0% | — | — | — | — |
| Op CF | -18.5M | -21.2M | -19.1M | -17.7M | -12.2M | — | -11.4M | — | — | — |
| Inv CF | 19.5M | -2.3M | -0.3M | -63.4K | -0.2M | — | — | — | — | — |
| Fin CF | 25.1M | 23.9M | -1.5M | 10.1M | 8.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CLBX.L are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CLBX.L | CelLBxHealth plc(you) | $39M | 16 | STRONG SELL |
| GDR.L | genedrive plc | $28M | 16 | STRONG SELL |
| EDX.L | EDX Medical Group Plc | $65M | 6 | STRONG SELL |
| ABDX.L | Abingdon Health Plc | $34M | 41 | HOLD |
| HVO.L | hVIVO plc | $63M | 36 | HOLD |
| SAR.L | Sareum Holdings plc | $38M | 19 | STRONG SELL |
| SBTX.L | SkinBioTherapeutics plc | $42M | 19 | STRONG SELL |
| MREO | Mereo BioPharma Group plc | $50M | 6 | STRONG SELL |
| IXI.L | IXICO plc | $25M | 24 | SELL |
| MPAL.L | MEDPAL AI PLC ORD 0.02P | $37M | 1 | STRONG SELL |
Peer medians: ROE 0.2% · P/E 24.7x · Gross margin 56.9%